

# Chiara Martinelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2088555/publications.pdf>

Version: 2024-02-01

31  
papers

1,526  
citations

623734

14  
h-index

580821

25  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2566  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tannic Acid-iron Complex-Based Nanoparticles as a Novel Tool against Oxidative Stress. ACS Applied Materials & Interfaces, 2022, 14, 15927-15941.	8.0	32
2	<i>In vitro</i> study of polydopamine nanoparticles as protective antioxidant agents in fibroblasts derived from ARSACS patients. Biomaterials Science, 2022, 10, 3770-3792.	5.4	10
3	Multiple roles of circulating tumor cells and exosomes in cancer metastasis. , 2022, , 7-21.		0
4	Smart Nanocarriers for Targeted Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 546-557.	1.7	3
5	Micro structured tools for cell modeling in the fourth dimension. , 2021, , .		1
6	Regulation of Hippo, TGF $\beta$ /SMAD, Wnt/ $\beta$ -Catenin, JAK/STAT, and NOTCH by Long Non-Coding RNAs in Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 657965.	2.8	13
7	Light-Activated Biomedical Applications of Chlorophyll Derivatives. Macromolecular Bioscience, 2021, 21, e2100181.	4.1	22
8	Cerium Oxide Nanoparticle Administration to Skeletal Muscle Cells under Different Gravity and Radiation Conditions. ACS Applied Materials & Interfaces, 2021, 13, 40200-40213.	8.0	8
9	Light-Activated Biomedical Applications of Chlorophyll Derivatives. Macromolecular Bioscience, 2021, 21, 2170027.	4.1	0
10	Antioxidants and Nanotechnology: Promises and Limits of Potentially Disruptive Approaches in the Treatment of Central Nervous System Diseases. Advanced Healthcare Materials, 2020, 9, e1901589.	7.6	50
11	What does the future hold for chemotherapy with the use of lipid-based nanocarriers?. Future Oncology, 2020, 16, 81-84.	2.4	6
12	ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Medicine, 2020, 18, 349.	5.5	8
13	Hybrid Magnetic Nanovectors Promote Selective Glioblastoma Cell Death through a Combined Effect of Lysosomal Membrane Permeabilization and Chemotherapy. ACS Applied Materials & Interfaces, 2020, 12, 29037-29055.	8.0	42
14	Development of Nanostructured Lipid Carriers for the Delivery of Idebenone in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay. ACS Omega, 2020, 5, 12451-12466.	3.5	16
15	Reproducibility warning: The curious case of polyethylene glycol 6000 and spheroid cell culture. PLoS ONE, 2020, 15, e0224002.	2.5	4
16	Nanotechnological approaches for counteracting multidrug resistance in cancer. , 2020, 3, 1003-1020.		4
17	Innovative approaches for cancer treatment: current perspectives and new challenges. Ecanermedicalscience, 2019, 13, 961.	1.1	450
18	Nanostructured carriers as innovative tools for cancer diagnosis and therapy. APL Bioengineering, 2019, 3, 011502.	6.2	164

#	ARTICLE	IF	CITATIONS
19	Regulation of Cell Signaling Pathways by Berberine in Different Cancers: Searching for Missing Pieces of an Incomplete Jig-Saw Puzzle for an Effective Cancer Therapy. <i>Cancers</i> , 2019, 11, 478.	3.7	42
20	Multifunctional temozolomide-loaded lipid superparamagnetic nanovectors: dual targeting and disintegration of glioblastoma spheroids by synergic chemotherapy and hyperthermia treatment. <i>Nanoscale</i> , 2019, 11, 21227-21248.	5.6	56
21	Human serum albumin nanoparticles loaded with phthalocyanine dyes for potential use in photodynamic therapy for atherosclerotic plaques. <i>Precision Nanomedicine</i> , 2019, 2, 279-302.	0.8	3
22	Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. <i>Nature Materials</i> , 2018, 17, 195-203.	27.5	331
23	Signaling Landscape of AML: The Story So Far. , 2018, , 233-262.		0
24	Exosomes: New Biomarkers for Targeted Cancer Therapy. , 2017, , 129-157.		7
25	Exploring the pH Sensitivity of Poly(allylamine) Phosphate Supramolecular Nanocarriers for Intracellular siRNA Delivery. <i>ACS Applied Materials &amp; Interfaces</i> , 2017, 9, 38242-38254.	8.0	38
26	An intrabody specific for the nucleophosmin carboxy-terminal mutant and fused to a nuclear localization sequence binds its antigen but fails to relocate it in the nucleus. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2014, 3, 27-33.	4.4	5
27	Erythrocyte Incubation as a Method for Free-Dye Presence Determination in Fluorescently Labeled Nanoparticles. <i>Molecular Pharmaceutics</i> , 2013, 10, 875-882.	4.6	20
28	The concurrent use of N- and C-terminal antibodies anti-nucleophosmin 1 in immunofluorescence experiments allows for precise assessment of its subcellular localisation in acute myeloid leukaemia patients. <i>Leukemia</i> , 2012, 26, 159-162.	7.2	7
29	A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. <i>Blood</i> , 2010, 116, 2096-2102.	1.4	35
30	Antibody-mediated purification of co-expressed antigen-antibody complexes. <i>Protein Expression and Purification</i> , 2010, 72, 55-58.	1.3	14
31	Immunological applications of single-domain llama recombinant antibodies isolated from a naïve library. <i>Protein Engineering, Design and Selection</i> , 2009, 22, 273-280.	2.1	135